Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio 45701, United States.
Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, Ohio 43210, United States.
World J Gastroenterol. 2023 Jan 21;29(3):413-424. doi: 10.3748/wjg.v29.i3.413.
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death worldwide. Despite the advent of screening efforts and algorithms to stratify patients into appropriate treatment strategies, recurrence rates remain high. In contrast to first-line treatment for HCC, which relies on several factors, including clinical staging, tumor burden, and liver function, there is no consensus or general treatment recommendations for recurrent HCC (R-HCC). Locoregional therapies include a spectrum of minimally invasive liver-directed treatments which can be used as either curative or neoadjuvant therapy for HCC. Herein, we provide a comprehensive review of recent evidence using salvage loco-regional therapies for R-HCC after failed curative-intent.
肝细胞癌 (HCC) 是全球癌症相关死亡的第二大主要原因。尽管已经开展了筛查工作，并制定了用于将患者分层至适当治疗策略的算法，但复发率仍然很高。与 HCC 的一线治疗不同，一线治疗取决于多个因素，包括临床分期、肿瘤负荷和肝功能，对于复发性 HCC (R-HCC)，尚无共识或普遍的治疗建议。局部区域治疗包括一系列微创肝脏靶向治疗，可以作为 HCC 的根治性或新辅助治疗。在此，我们综述了近期关于在根治性治疗失败后使用挽救性局部区域治疗 R-HCC 的证据。
